pic

Geographic Disparities Found in Cancer Diagnosis Stage, Mortality for AYAs

Dec 19, 2023
For adolescents and young adults (AYAs) with cancer, living in rural counties and living farther from the reporting hospital are associated with later-stage diagnoses and increased mortality, according to a study published online Read more…

Geographic Disparities Found in Cancer Diagnosis Stage, Mortality for AYAs

For adolescents and young adults (AYAs) with cancer, living in rural counties and living farther from the reporting hospital are associated with later-stage diagnoses and increased mortality, according to a study published online July 8 in Cancer. Kimberly J. Johnson, M.P.H., Ph.D., from Washington University in St. Louis, and colleagues obtained data on AYAs aged 15 to 39 years who were diagnosed with cancer from 2010 to 2014. Residence in metropolitan (metro), urban, or rural counties was defined at the time of diagnosis. The distance between the patient’s residence and the reporting hospital was classified as short, intermediate, or long. The stage analysis included 146,418 AYAs, while the survival analysis included 178,688 AYAs. The researchers found that the odds of having a late versus early stage at diagnosis (stages III and IV versus I and II) were increased for those living in rural versus metro counties and for those living at long versus short distances to the reporting hospital (odds ratios, 1.16 and 1.20, respectively). The risk for death was increased for those living in rural versus metro counties and for long versus short distances to the reporting hospital (hazard ratios, 1.17 and 1.30, respectively). Of the associations between metro, urban, or rural residence and residential distance categories and survival, 54 and 31 percent, respectively, was mediated by disease stage.

Read More…

 

Related Posts 

Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care

Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…

FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication

The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…

Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women

Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…